Vol. 92, Suppl. 1, 2010
Issue release date: September 2010
Neuroendocrinology 2010;92(suppl 1):6–10
Add to my selection

Genetics of Cushing’s Syndrome

Yaneva M.a, b · Vandeva S.a, b · Zacharieva S.a · Daly A.F.b · Beckers A.b
aClinical Center of Endocrinology, Medical University, Sofia, Bulgaria; bDepartment of Endocrinology, University of Liège, Liège, Belgium
email Corresponding Author


 goto top of outline Key Words

  • Cushing’s disease
  • Cushing’s syndrome
  • Multiple endocrine neoplasia type 1
  • Carney complex
  • Familial isolated pituitary adenomas
  • Aryl hydrocarbon receptor-interacting protein

 goto top of outline Abstract

Cushing’s syndrome (CS) is characterized by pathologically elevated free glucocorticoid levels. Endogenous hypercortisolism is usually due to ACTH-secreting pituitary corticotropic adenomas and less often due to ectopic ACTH-secreting neuroendocrine neoplasms or ACTH-independent adrenal cortisol hypersecretion. CS is a serious chronic disease leading to a several-fold increase in cardiovascular morbidity and mortality. Multiple genetic alterations have been described in the setting of sporadic corticotropinoma formation. Changes in the expression profiles have been demonstrated in growth factors and their receptors, cell-cycle regulators and in various genes related to hormonal gene transcription, synthesis and secretion. Sporadic adrenal adenomas and carcinomas may demonstrate dysfunction in genes such as TP53 among others. Cushing’s disease can be an inherited condition also. Multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenomas (FIPA) together account for 5% of pituitary adenomas. Cushing’s disease occurs infrequently in an inherited setting in both of these conditions. To date only 2 cases of Cushing’s disease have been described in association with mutations in AIP. One case of Cushing’s disease has been reported as part of MEN4, a rare MEN1-like syndrome due to mutation in the CDKN1B gene. Carney complex (CNC) due to PRKAR1A mutations in most cases is associated with CS, mainly as a cause of bilateral adrenal hyperplasia. The cAMP signaling pathway is affected in this setting. In recent times the involvement of genes such as PDE11A, PDE8B and others have expanded the spectrum of the genetic pathophysiology of CS.

Copyright © 2010 S. Karger AG, Basel

goto top of outline Introduction

Cushing’s syndrome (CS) has been described for about a century and represents a classical syndrome in endocrinology. Recent years have been marked by progress in elucidating the etiology and the pathogenesis of the disease. In this short review, we summarize some of the molecular genetic information of most relevance to the causation of CS.


goto top of outline Cushing’s Disease

An ACTH-secreting pituitary adenoma (corticotropinoma) is the commonest cause of CS, accounting for approximately 75–80% of cases. A number of studies have examined the genetic alterations underlying sporadic corticotropinoma formation. Several changes in the pituitary-specific signaling pathways have been found. For instance, Morris et al. [1] found loss of expression of the ACTH-receptor gene in corticotropic adenomas in patients with Cushing’s disease. However, mutations in the ACTH receptor have not been found in this setting [1]. Similarly, while the glucocorticoid receptor (GR) and the CRH receptor have increased expression in corticotropic adenomas, they are not characteristically associated with mutations in Cushing’s disease [2,3]. While the vasopressin receptor subtype 3 (V3R) is expressed in all corticotropic adenomas, no mutation of the V3R gene has been demonstrated to date [4]. It was found that the function of 11 β-hydroxysteroid dehydrogenase (11β-HSD), an enzyme that could have a significant pre-receptor role in regulating the corticosteroid hormone action, is altered in corticotropic adenomas. However, the role of these functional derangements remains unclear [5].

The hallmark of ACTH-secreting pituitary adenomas is their resistance to glucocorticoids (GC) and their unresponsiveness to normal GC negative feedback. Molecular analysis of the normal mechanism of GC feedback led to identification of two essential proteins for pro-opiomelanocortin repression, the expression of which are often dysregulated in corticotropic adenomas thus providing a potential molecular explanation for GC resistance [6]. These two proteins, Brg1 (the ATPase subunit of the Swi/Snf complex) and histone deacetylase 2 (HDAC2), are involved in chromatin remodeling and may also participate in the tumorigenic process, as Brg1 is a tumor suppressor [7]. In some adenomas Brg1 is expressed but delocalized to the cytoplasm of the tumor cells. These tumors retained responsiveness to high-dose GC.

Most often Cushing’s disease occurs as a sporadic, isolated condition. Rarely, it can appear as a component of genetic syndromes such as multiple endocrine neoplasia type 1 (MEN1), Carney complex (CNC) and in the setting of familial isolated pituitary adenomas (FIPA). MEN1 is a familial disorder with autosomal-dominant transmission, due to an inactivating mutation in the MEN1 gene located in chromosome 11q13 [8]. The prevalence of pituitary disease among MEN1 patients is about 40% [9]. Pituitary adenomas are mainly prolactin-secreting, of which 85% are macroadenomas. Corticotropinomas in MEN1 are rare (6/136 in the series of Verges et al. [9]). No significant difference was found in their prevalence comparing a cohort of patients with sporadic pituitary adenomas [9]. Regarding extrapituitary CS, genetic abnormalities in the region of the MEN1 gene are common, with loss of heterozygosity (LOH) at 11q13 being observed in more than 90% of adrenocortical carcinomas and 20% of adrenocortical adenomas.

Recently, it was shown that patients with a MEN1-like phenotype but negative for a MEN1 mutation could harbor mutations in the cyclin-dependent kinase inhibitor 1B gene (CDKN1B, expressing p27kip1) [10]. CDKN1B is located in chromosome 12. Patients with these mutations have a pluritumoral syndrome, termed multiple endocrine neoplasia type 4 (MEN4), however, the condition is extremely rare. Cushing’s disease may be part of this syndrome (described in only 1 patient with MEN4) [11].

FIPA is a clinical entity first described in the late 1990s in which two or more cases of pituitary adenomas occur in related members of a kindred in the absence of MEN1 or CNC. Mutation of the aryl hydrocarbon receptor-interacting protein (AIP) gene located on chromosome 11q13–32 has been described in 15% of these patients. CD is rare in FIPA families. In a study comprising 138 patients (within 64 families), eight patients were affected by CD in five FIPA families (in two families, there was homogeneous expression of Cushing’s disease in affected members) [12]. Patients with Cushing’s disease within FIPA were negative for AIP mutations, but sporadic cases of Cushing’s disease have been reported in association with germline AIP mutations, one of them a child [13].


goto top of outline Extrapituitary Disease

Two other inherited diseases, McCune-Albright syndrome (MAS) and CNC are associated with CS, mainly bilateral adrenal hyperplasia. The c-AMP signaling pathway is affected in both conditions. CNC is a multiple neoplasia syndrome with an autosomal dominant transmission. Inactivating germline mutations in the gene coding for PRKAR1A – one of the regulatory subunits of PKA – have been found [14]. The gene coding for PRKAR1A is located on chromosome 17q22–23. All described mutations (small or large deletions, base substitutions, etc.) usually lead to a premature stop codon [15]. It has been noted that mutation can also result in an expression of abnormal protein, thus demonstrating that alteration of PRKAR1A function (not merely its absence) could augment PKA activity leading to tumorigenesis in tissues affected by CNC [16]. More than 60% of CNC patients harbor pathogenic PRKAR1A mutations. Patients with sporadic primary pigmented nodular adrenocortical disease (PPNAD) may also harbor this mutation [17]. Other loci located on chromosome 2 (2p16, 2q31.2 regions) have been implicated in the tumorigenesis of CNC. Inactivating mutations in the phosphodiesterase11A (PDE11A) gene, located on chromosome 2q31.2, has been described in patients with PPNAD negative for PRKAR1A mutations [14,18]. These patients present with micronodular adrenocortical disease with limited or absent pigment, mostly occurring as an isolated or sporadic disease in early childhood. Inactivating mutations in PDE11A lead to a disruption of the ability to hydrolyze cAMP and cGMP. Some of the mutated sequences are frequent in the general population, thus revealing the PDE11A gene mutation as possible predisposing factor to a number of tumors. A mutation in the gene coding for PDE8B (locus 5q13) has been described resulting in disrupted ability for cAMP hydrolysis.

ACTH-independent macronodular adrenal hyperplasia (AIMAH) is responsible for less than 1% of endogenous CS [19]. Most often it appears as a sporadic disease. There are several reports of familial forms of AIMAH with autosomal dominant transmission. Substantial progress has been made in elucidating the mechanism of cortisol production in AIMAH, previously described as ‘autonomous’. It has been found that hypercortisolism can be the result of ectopic expression of aberrant receptors, such as glucose-dependent insulinotropic peptide (GIP) receptor, β-adrenergic receptors, vasopressin (V2–V3) receptor, serotonin (5-HT7), angiotensin-II receptor (AT1R) and glucagon receptors. An increased expression or altered activity of eutopic receptors such as gonadotropin (LH/hCGR), serotonin (5-HT4) and probably leptin receptors has also been associated with AIMAH [19]. The presence of aberrant receptors in AIMAH can be explained by a germline mutation (in the familial forms) or by a somatic mutation at an early stage of embryogenesis that involves both adrenal cortices [19]. The protein kinase A (PKA) signaling pathway was shown to be altered in AIMAH. Somatic losses of the 17q22–24 region, alterations of the PKA subunit expression, and activity changes have been demonstrated [20]. A variation in the gene encoding phosphodiesterase 11A4 implicated in the regulation of cyclic nucleotide levels has been described [21].

Adrenocortical adenomas (ADA) and carcinomas (ACC), the most frequent cause of adrenal CS, may appear isolated or in a familial setting (Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, familial adenomatous polyposis coli and MEN1). ACC are of monoclonal origin, whereas ADA might be monoclonal as well as polyclonal [22]. Chromosomal alterations are observed in 28% of benign tumors and up to 62% of ACC. Changes in expression of the insulin-like growth factor II gene (IGF-II), located at 11p15, may play a role in adrenocortical tumorigenesis [23]. In sporadic ACC, IGF-II is overexpressed in approximately 90% of the cases. Genetic (CDKN1C) or epigenetic (KCNQ10T, H19) changes in the imprinted region of 11p15 have been shown to cause Beckwith-Wiedemann syndrome [24]. Uniparental disomy is more frequent in ACC than in adrenal adenomas, correlates with Weiss score and is associated with high risk of tumor recurrence [25]. It has been proposed as a strong biological marker for predicting ACC malignancy after surgery [25]. The tumor suppressor gene TP53, located in chromosome 17p13, plays an important role in cell proliferation. A somatic mutation of TP53 has been demonstrated in 25–35% of adults with sporadic ACC [26]. In children with apparently sporadic ACC this mutation is more frequent – 50–80%. A specific germline mutation of the TP53 gene (R337) has been demonstrated in Brazilian pediatric patients [27]. In 70% of the families with Li-Fraumeni syndrome, germline mutation in TP53 is found. Allelic loss (LOH) at the TP53 locus (17p13) is observed in 85% of ACC and in less than 30% of benign adenomas thus revealing that 17p13 could be used as a molecular marker of malignancy in adrenocortical tumors [23].

The Wnt/β-catenin signaling pathway is another important factor in adrenal cortex functioning. Germline mutation of the APC (adenomatous polyposis coli) gene leads to activation of the Wnt/β-catenin pathway and thus to the development of familial adenomatous polyposis coli. These patients can harbor adrenal cortical tumors. β-catenin somatic mutations that alter the glycogen synthase kinase 3-β (GSK3-β) phospohorylation site may be found in 25–30% of ACC patients [28]. These mutations are also seen in adrenocortical adenomas and PPNAD.


goto top of outline Conclusion

Significant progress is being made in understanding the molecular genetic mechanisms of tumor pathogenesis CS, especially in the field of adrenal CS (table 1). Nevertheless, in both pituitary and extrapituitary disease, a wealth of opportunities remain to delineate and characterize novel genetic and epigenetic mechanisms of tumorigenesis and growth in the settings of sporadic and familial CS.

Table 1. Genetic abnormalities in pituitary adenomas


goto top of outline Disclosure Statement

The authors declare no conflicts of interest.

 goto top of outline References
  1. Morris DG, Kola B, Borboli N, et al: Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J Clin Enodocinol Metab 2003;88:6080–6087.
  2. Dahia PL, Honegger J, Reincke M, et al: Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. J Clin Endocrinol Metab 1997;82:1088–1093.
  3. Dieterich KD, Gundelfinger ED, Ludecke DK, et al: Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1998;83:3327–3331.
  4. de Keyzer Y, Rene P, Beldjord C, et al: Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor gene in corticotroph tumors. Clinical Endocrinology 1998;49:475–482.
  5. Rabbitt EH, Ayuk J, Boelaert K, et al: Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene 2003;22:1663–1667.
  6. Drouin J, Bilodeau S, Valette S: Of old and new disease: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 2007;72:175–182.
  7. Bilodeau S, Valette-Kasic S, Gauthier Y, et al: Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing’s disease. Genes Dev 2006;20:2871–2886.
  8. Burgess JR, Greenaway TM, Shepherd JJ: Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243:465–470.
  9. Vergès B, Boureille F, Goudet P, et al: Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87:457–465.
  10. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al: Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558–15563.
  11. Georgitsi M, Raitila A, Karhu A, et al: Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321–3325.
  12. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316–3323.
  13. Pereira AM, Hes FJ, Horvath A, et al: Association of the M1V PRKAR1A mutation with primary pigmented nodular adrenocortical disease in two large families. J Clin Endocrinol Metab 2010;95:338–342.
  14. Kirschner LS, Carney JA, Pack SD, et al: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89–92.
  15. Kirschner LS, Sandrini F, Monbo J, et al: Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037–3046.
  16. Groussin L, Kirschner LS, Vincent-Dejean C, et al: Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002;71:1433–1442.
  17. Groussin L, Jullian E, Perlemoine K, et al: Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 2002;87:4324–4329.
  18. Horvath A, Boikos S, Giatzakis C, et al: A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006;38:794–800.
  19. Lacroix A: ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:245–259.
  20. Bourdeau I, Matyakhina L, Stergiopoulos SG, et al: 17q22–24 chromosomal losses and alterations of protein kinase a subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2006;91:3626–3632.
  21. Hsiao HP, Verma S, Boikos SA, et al: A molecular and clinical genetic investigation of ACTH-independent macronodular adrenal hyperplasia compared to other, common adrenocortical tumors: evidence for heterogeneity, overlap with other tumor syndromes and frequent but atypical hormonal secretion. 89th Annual Meeting of the Endocrine Society, Toronto, 2007, p 403, abstr P2-299.
  22. Gicquel C, Leblond-Francillard M, Bertagna X, et al: Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 1994;40:465–477.
  23. Bertherat J, Bertagna X: Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009;23:261–271.
  24. Lam WW, Hatada I, Ohishi S, et al: Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet 1999;36:518–523.
  25. Gicquel C, Bertagna X, Gaston V, et al: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001;61:6762–6767.
  26. Libe R, Groussin L, Tissier F, et al: Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007;13:844–850.
  27. Latronico AC, Pinto EM, Domenice S, et al: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001;86:4970–4973.
  28. Tissier F, Cavard C, Groussin L, et al: Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005;65:7622–7627.

 goto top of outline Author Contacts

Albert Beckers
Department of Endocrinology, CHU de Liège
Domaine Universitaire du Sart-Tilman
BE–4000 Liège (Belgium)
Tel. +32 4 366 7083 or 8226, Fax +32 4 366 7261, E-Mail albert.beckers@chu.ulg.ac.be

 goto top of outline Article Information

Published online: September 10, 2010
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 1, Number of References : 28

 goto top of outline Publication Details

Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships)

Vol. 92, No. Suppl. 1, Year 2010 (Cover Date: September 2010)

Journal Editor: Millar R.P. (Edinburgh)
ISSN: 0028-3835 (Print), eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.